Sectors

Non-dilutive Pharmaceuticals funding in Ireland

Pharmaceuticals funding in Ireland typically combines the R&D tax credit (a predictable, legislated incentive) with selective pharmaceuticals grants (competitive, time bound, often collaborative). For CFOs, the value is faster cash-flow, lower cost of capital on strategic development work, and a clearer audit trail on what is and is not “qualifying R&D”. FI Group aligns tax, grants and evidence into one defensible funding strategy.

If you want a CFO-ready view of value, timing and risk, speak to an FI Group specialist for a rapid eligibility and funding roadmap.

What is pharmaceuticals funding and how does it work?

Pharmaceuticals funding is the mix of tax incentives and non-dilutive supports that reduce the net cost of qualifying innovation, from discovery and formulation through process development, scale-up and validated manufacture. In Ireland, the core levers are the R&D tax credit, Enterprise Ireland supports for indigenous firms, IDA Ireland supports for FDI operations, and competitive collaborative funds.

For finance teams, the practical question is not “what is available?”, it is “what is bankable, compliant, and deliverable with our internal bandwidth?”

Space technology funding in Ireland is most powerful when you treat R&D tax, ESA-linked grants, and venture capital as one joined-up capital plan. The Irish R&D Corporation Tax Credit can return cash against qualifying R&D spend, while ESA Space Solutions and EU programmes can fund earlier technical validation and market pull. FI Group aligns eligibility, evidence, and timing so your funding stack strengthens runway without increasing compliance risk.
Message FI Group on LinkedIn to sanity-check your funding strategy and build a board-ready plan.

What is space technology funding and how does it work in Ireland?

Space technology funding is the mix of tax-based incentives, non-dilutive grants, and equity finance used to de-risk development and accelerate commercialisation of space and space-enabled products.

In practice, Irish space funding usually combines:

• R&D Corporation Tax Credit for qualifying science and technology work
• ESA programmes accessed via Ireland’s ESA membership and local delivery partners
• Enterprise Ireland supports for innovation, scaling, and export growth
• EU funding for collaborative and strategic space capability
• VC and strategic investment to scale once technical and market risk are reduced

CFO lens: the objective is not “max funding”. It is predictable cash flow, low audit risk, and a credible capital story for investors and boards.

AI funding in Ireland: a CFO-led route to non-dilutive capital and stronger cash flow

AI funding in Ireland typically combines AI grants (project co-funding, feasibility support, collaboration funding) with R&D tax for AI (a corporation tax credit based on qualifying R&D spend). For CFOs, the prize is measurable: reduced cost of capital, longer runway, and a funding strategy that stands up to due diligence and audit scrutiny. FI Group helps you select the right funding mix, build defensible technical and financial evidence, and execute claims and applications with board-ready governance.

CTA: If you want a finance-first view of your eligible AI activities and the fastest path to cash, message FI Group Ireland on LinkedIn to book an AI funding diagnostic.

What is AI funding and how does it work in Ireland?

AI funding is the combination of non-dilutive supports that reduce the net cost of building and scaling AI capability, typically through grants, collaborative programmes, and the Irish R&D tax credit. In practice, CFOs structure AI funding as a portfolio: quick-win feasibility supports, scalable R&D tax credit cash flow, and larger competitive grant programmes aligned to product roadmap milestones.

AI businesses in Ireland generally fund innovation through three complementary channels:

• R&D tax for AI: A credit linked to qualifying R&D expenditure, often the most repeatable source of non-dilutive value once eligibility and governance are embedded.
• AI grants: Competitive or entitlement-style supports for feasibility, R&D delivery, partnerships with Irish research organisations, and commercialisation readiness.
• VC and strategic capital: Used to accelerate scale, often strengthened by a credible non-dilutive plan that reduces burn and execution risk.

The CFO lens: treat grants as milestone capital, and treat the R&D tax credit as an embedded cash flow lever that improves unit economics over time.

Non-dilutive manufacturing funding

Manufacturing funding combines R&D tax and manufacturing grants to reduce the cost of product, process and sustainability innovation in Ireland. For CFOs, it is a cash flow lever that can de-risk capex, protect margin, and improve the internal rate of return on industrial programmes. FI Group Ireland helps you identify eligible activity, build evidence-grade documentation, and coordinate grants and tax so your funding stack is optimised and defensible.

If you want a fast view of your potential claim value and the grant routes that fit your factory roadmap, speak to an FI Group Ireland specialist.

What is manufacturing funding, and why does it matter to CFOs?

Manufacturing funding is non-dilutive finance that offsets the cost of industrial innovation, typically through Ireland’s R&D corporation tax credit and targeted grant supports. It matters because it converts uncertainty into a quantified business case, accelerates payback, and reduces the cash burden of programmes that boards scrutinise heavily.

In manufacturing, funding is rarely a “nice to have”. It is a practical response to CFO realities:

• Margin pressure from energy, labour and input volatility
• Capex competition across plants, lines and regions
• Regulatory and customer compliance requirements that drive unplanned investment
• Internal resourcing constraints across finance, engineering and operations
• Audit and enquiry risk if claims are poorly evidenced or inconsistent across years

What is biotech funding and why does it matter for CFOs?

Biotech funding is the combined use of Ireland’s R&D tax credit and non-dilutive biotech grants to extend runway, reduce cost of capital, and de-risk regulatory and technical milestones without over-relying on equity. FI Group Ireland helps you quantify claimable R&D, map the right grant routes, and build audit-ready evidence.

Speak to an FI Group specialist for a CFO-grade biotech funding map, including cash timing, controls, and risk.

What does “R&D tax for biotech” mean in Ireland?

R&D tax for biotech refers to qualifying scientific and technological work that seeks to resolve uncertainty through systematic investigation, and which meets Ireland’s R&D tax credit criteria. In biotech, this often spans discovery, pre-clinical, CMC, process development, analytical methods, and scale-up, provided the work is not routine and the uncertainty is real.

Biotech CFOs typically see three practical levers:

• Cash acceleration: converting eligible spend into a predictable cashflow profile.
• Governance: aligning technical narratives, cost capture, and controls with Revenue expectations.
• Portfolio clarity: separating genuine R&D from QA, validation-as-usual, and commercial manufacturing.

What is non-dilutive fintech funding in Ireland, and why does it matter for CFOs?

Non-dilutive Fintech funding in Ireland is the combination of R&D tax for fintech and non-dilutive supports such as fintech grants, designed to reduce burn, de-risk delivery, and extend runway without rewriting your cap table. Done well, it turns innovation spend into predictable cash flow and audit-ready governance.

If you want a board-ready funding plan that joins up tax, grants, and investor expectations, speak to FI Group Ireland.

What does “non-dilutive fintech funding” actually include?

Fintech funding typically includes the Irish R&D Corporation Tax Credit, Irish agency grants, and EU programmes, aligned to the technical work that creates defensible capability. For CFOs, the strategic value is choosing the right mix: near-term liquidity from R&D tax, targeted de-risking from grants, and longer-horizon acceleration through collaborative programmes.

Most fintechs draw from three buckets:

• Tax based funding: R&D Corporation Tax Credit (cashflow via instalments, with compliance obligations)
• Irish agency funding: Enterprise Ireland and IDA Ireland supports (innovation, RD&I, collaboration, scaling)
• EU funding: Horizon Europe, Digital Europe, Eurostars, and EIC routes (consortia, higher scrutiny, larger potential awards)